Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS Houston, Texas, USA – April 11, 2022 (GLOBE NEWSWIRE) –…
Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board Houston, TX, USA, March 8, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. of Houston, Texas,…
Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development Houston, TX, USA, March 1st, 2022 (GLOBE NEWSWIRE) — Invectys, Inc. of Houston,…
Invectys is looking for a Senior Research Associate with expertise in Biotechnology/Immuno-Oncology to be part of our CAR-T Preclinical Development department based…
Invectys, a Biopharmaceutical Company developing Innovative Immunotherapy products for the treatment of cancers and disorders of the immune system is looking for…
Invectys to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference Houston, Texas, USA – January 6th, 2022 (GLOBE NEWSWIRE) –…
Houston, Texas, USA, Dec. 16, 2021 (GLOBE NEWSWIRE) — Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development…
Houston, Texas, USA, Sept. 07, 2021 (GLOBE NEWSWIRE) — Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the…
